致编辑信件的回复：复发性乳腺癌原发部位与转移部位之间雌激素受体的不一致性及Ki67的变化 - Suppr | 超能文献

Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer.

作者信息

Watanabe Junichiro

机构信息

Division of Breast Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Shizuoka, 4118777, Japan.

出版信息

Breast Cancer Res Treat. 2020 Jul;182(2):513-514. doi: 10.1007/s10549-020-05695-2. Epub 2020 May 21.

DOI:10.1007/s10549-020-05695-2

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer.致编辑信件的回复：复发性乳腺癌原发部位与转移部位之间雌激素受体的不一致性及Ki67的变化

Breast Cancer Res Treat. 2020 Jul;182(2):513-514. doi: 10.1007/s10549-020-05695-2. Epub 2020 May 21.

2

Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.浸润性淋巴细胞、肿瘤特征与早期乳腺癌患者复发。

Am J Clin Oncol. 2013 Jun;36(3):224-31. doi: 10.1097/COC.0b013e3182467d90.

3

Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.原发性乳腺癌与配对转移瘤的比较：生物标志物不一致对结局和治疗的影响。

Future Oncol. 2018 Apr;14(9):849-859. doi: 10.2217/fon-2017-0384. Epub 2018 Mar 12.

4

[Discordance of Estrogen Receptor,Progesterone Receptor,Cerb-B2,Ki-67 Index and P53 Expressions between Primary and Recurrent or Metastatic Sites in Breast Cancer Patients].[乳腺癌患者原发灶与复发或转移灶之间雌激素受体、孕激素受体、Cerb-B2、Ki-67指数及P53表达的不一致性]

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019 Oct 30;41(5):673-677. doi: 10.38/j.issn.1000-503X.10940.

5

Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.在雌激素受体阳性/HER2 阴性已行手术的乳腺癌中，肿瘤浸润淋巴细胞的预后意义可能因 Ki67 表达水平而异。

Breast Cancer. 2019 Nov;26(6):738-747. doi: 10.1007/s12282-019-00977-0. Epub 2019 May 16.

6

Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.肿瘤浸润淋巴细胞在接受节拍化疗的激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌中的不良预后作用

Breast. 2017 Aug;34:83-88. doi: 10.1016/j.breast.2017.05.009. Epub 2017 May 23.

7

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.原发性乳腺癌及其配对转移灶中激素受体、人表皮生长因子受体-2 和 Ki67 的不一致性：临床影响。

Oncology. 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.

8

Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters.乳腺癌中的肿瘤浸润淋巴细胞。与临床和病理参数的关联。

Bull Exp Biol Med. 2018 Dec;166(2):241-244. doi: 10.1007/s10517-018-4323-3. Epub 2018 Nov 28.

9

Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.肿瘤浸润淋巴细胞（TILs）的形态学评估以研究浸润性乳腺癌的免疫原性、揭示淋巴细胞网络并辅助复发预测：一项回顾性研究

Int J Mol Sci. 2017 Sep 8;18(9):1936. doi: 10.3390/ijms18091936.

10

[Expression discordances and clinical values of ER, PR, HER-2 and Ki-67 in primary and metastatic breast cancer].[原发性和转移性乳腺癌中ER、PR、HER-2及Ki-67的表达差异与临床价值]

Zhonghua Zhong Liu Za Zhi. 2019 Sep 23;41(9):681-685. doi: 10.3760/cma.j.issn.0253-3766.2019.09.007.

引用本文的文献

1

Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer.与基于CDK4/6抑制剂的治疗在转移性乳腺癌中的疗效相关的临床病理特征

Breast Cancer (Auckl). 2022 Jan 5;16:11782234211065148. doi: 10.1177/11782234211065148. eCollection 2022.

2

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status.用于预测表皮生长因子受体突变状态的非小细胞肺癌患者一线酪氨酸激酶抑制剂或化疗反应的Ki-67增殖指数相关列线图

Front Med (Lausanne). 2021 Nov 5;8:728575. doi: 10.3389/fmed.2021.728575. eCollection 2021.